This multicenter analysis included 104
HIV/HBV coinfected patients treated with ART regimens containing
tenofovir. Again, most (about 90%) were men, the age range was similar, and about 60% were white; about two-thirds were HBeAg positive at baseline.
The investigators measured HBsAg levels at baseline, month 6, and then annually; the median duration of follow-up was 56 months (range 8-97 months). HBsAg clearance is generally considered a cure, though "occult: or hidden HBV may remain.